PCN139 - COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHO ARE INELIGIBLE FOR CISPLATIN-CONTAINING CHEMOTHERAPY IN ENGLAND

Saved in:
Bibliographic Details
Published in:Value in health 2018-10, Vol.21, p.S38-S38
Main Authors: Tsoumani, E., Dillon, R.J., Zhong, Y., Prabhu, V.S., Xu, R., Li, H.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2018.09.222